(Q41444380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Shortening treatment of tuberculosis: lessons from fluoroquinolone trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Camus Nimmo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Patrick Phillips

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Andrew Nunn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Marc Lipman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Timothy McHugh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

19 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

141-143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

A Controlled Trial of 3-Month, 4-Month, and 6-Month Regimens of Chemotherapy for Sputum-smear-negative Pulmonary Tuberculosis: Results at 5 Years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

A four-month gatifloxacin-containing regimen for treating tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970885-0

7 January 2021

10.1016/S1473-3099(14)70885-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25749057%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference